{
    "id": 2132,
    "fullName": "BCR positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "BCR positive indicates the presence of the BCR gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 613,
        "geneSymbol": "BCR",
        "terms": [
            "BCR",
            "ALL",
            "BCR1",
            "CML",
            "D22S11",
            "D22S662",
            "PHL"
        ]
    },
    "variant": "positive",
    "createDate": "10/08/2014",
    "updateDate": "08/24/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10530,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ACP-319 treatment in BCR-driven chronic lymphocytic leukemia mouse models resulted in decreased phosphorylation of downstream signaling molecules in the BCR pathway, and improved survival of the mice (Cancer Res 2016;76(14 Suppl):Abstract nr 4797).",
            "molecularProfile": {
                "id": 2069,
                "profileName": "BCR positive"
            },
            "therapy": {
                "id": 3265,
                "therapyName": "ACP-319",
                "synonyms": null
            },
            "indication": {
                "id": 1040,
                "name": "chronic lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8312,
                    "pubMedId": null,
                    "title": "The combination of ACP-196 and ACP-319 leads to increased survival in the TCL1-192 CLL mouse model",
                    "url": "http://cancerres.aacrjournals.org/content/76/14_Supplement/4797.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10330,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Calquence (acalabrutinib) and ACP-319 combination treatment resulted in enhanced suppression of signaling pathways downstream of BCR, leading to tumor inhibition and increased survival in allograft models of BCR-driven chronic lymphocytic leukemia (Cancer Res 2016;76(14 Suppl):Abstract nr 4797).",
            "molecularProfile": {
                "id": 2069,
                "profileName": "BCR positive"
            },
            "therapy": {
                "id": 5466,
                "therapyName": "Acalabrutinib + ACP-319",
                "synonyms": null
            },
            "indication": {
                "id": 1040,
                "name": "chronic lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8312,
                    "pubMedId": null,
                    "title": "The combination of ACP-196 and ACP-319 leads to increased survival in the TCL1-192 CLL mouse model",
                    "url": "http://cancerres.aacrjournals.org/content/76/14_Supplement/4797.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11330,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BCR positive leukemia calls harboring TCF3-PBX1 demonstrated cell growth inhibition when treated with Sprycel (dasatinib) in culture (PMID: 27758892).",
            "molecularProfile": {
                "id": 27961,
                "profileName": "TCF3 - PBX1 BCR pos"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9240,
                    "pubMedId": 27758892,
                    "title": "E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27758892"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11337,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BCR positive leukemia cells harboring TCF3-PBX1 demonstrated inhibition of cell growth in culture and prolonged disease survival in cell line xenograft models when treated with A-770041 (PMID: 27758892).",
            "molecularProfile": {
                "id": 27961,
                "profileName": "TCF3 - PBX1 BCR pos"
            },
            "therapy": {
                "id": 5945,
                "therapyName": "A-770041",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9240,
                    "pubMedId": 27758892,
                    "title": "E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27758892"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11334,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BCR positive leukemia cells harboring TCF3-PBX1 demonstrated inhibition of cell proliferation when treated with RK22446 in culture (PMID: 27758892).",
            "molecularProfile": {
                "id": 27961,
                "profileName": "TCF3 - PBX1 BCR pos"
            },
            "therapy": {
                "id": 5946,
                "therapyName": "RK22446",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9240,
                    "pubMedId": 27758892,
                    "title": "E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27758892"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11338,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of A-770041 and PRT062607 resulted in synergistic cell growth inhibition in BCR positive leukemia cells harboring TCF3-PBX1 in culture (PMID: 27758892).",
            "molecularProfile": {
                "id": 27961,
                "profileName": "TCF3 - PBX1 BCR pos"
            },
            "therapy": {
                "id": 5947,
                "therapyName": "A-770041 + PRT062607",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9240,
                    "pubMedId": 27758892,
                    "title": "E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27758892"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11340,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Sprycel (dasatinib) and PRT062607 resulted in synergistic cell growth inhibition of BCR positive leukemia cells harboring TCF3-PBX1 in culture (PMID: 27758892).",
            "molecularProfile": {
                "id": 27961,
                "profileName": "TCF3 - PBX1 BCR pos"
            },
            "therapy": {
                "id": 5949,
                "therapyName": "Dasatinib + PRT062607",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9240,
                    "pubMedId": 27758892,
                    "title": "E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27758892"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11335,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BCR positive leukemia cells harboring TCF3-PBX1 demonstrated inhibition of cell growth in culture and prolonged disease survival in cell line xenograft models when treated with PRT062607 (PMID: 27758892).",
            "molecularProfile": {
                "id": 27961,
                "profileName": "TCF3 - PBX1 BCR pos"
            },
            "therapy": {
                "id": 3781,
                "therapyName": "PRT062607",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9240,
                    "pubMedId": 27758892,
                    "title": "E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27758892"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11339,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of A-770041 and R406 resulted in synergistic cell growth inhibition in BCR positive leukemia cells harboring TCF3-PBX1 in culture (PMID: 27758892).",
            "molecularProfile": {
                "id": 27961,
                "profileName": "TCF3 - PBX1 BCR pos"
            },
            "therapy": {
                "id": 5948,
                "therapyName": "A-770041 + Tamatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9240,
                    "pubMedId": 27758892,
                    "title": "E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27758892"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2069,
            "profileName": "BCR positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27961,
            "profileName": "TCF3 - PBX1 BCR pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}